3-methyl-3H-azepine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 英文名称: 3-methyl-3H-azepine
• 化学式: C₇H₉N
• 分子量: 107.15
• InChiKey: NDXNIYXJYKHKHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE BROMODOMAINES BET BICYCLIQUES ET LEURS UTILISATIONS
  申请人：STROVEL JEFFREY WILLIAM

  公开号：WO2017091661A1

  公开（公告）日：2017-06-01

  The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.

  本发明涉及结合并调节含有溴结构域蛋白的化合物，制备这些化合物的方法，含有这些化合物的药物组合物，以及使用这些化合物治疗各种疾病和疾病的方法。
• Muscarinic M1 receptor positive allosteric modulators
  申请人：SUVEN LIFE SCIENCES LIMITED

  公开号：US10308620B2

  公开（公告）日：2019-06-04

  The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.

  本发明涉及作为毒蕈碱 M1 受体正异位调节剂的式 (I) 化合物或立体异构体和药学上可接受的盐。本发明还涉及制备此类化合物的方法和包含此类化合物的药物组合物。本发明的化合物可用于治疗与毒蕈碱 M1 受体有关的各种疾病。
• MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：SUVEN LIFE SCIENCES LIMITED

  公开号：US20180155302A1

  公开（公告）日：2018-06-07

  The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.
• [EN] MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE<br/>[FR] DÉRIVÉS DE MAYTANSINOÏDE, LEURS CONJUGUÉS, ET PROCÉDÉS D'UTILISATION
  申请人：REGENERON PHARMA

  公开号：WO2017132173A1

  公开（公告）日：2017-08-03

  Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.